Problem

A leading pharmaceutical company, working with a biotech partner, wanted to create a long term Lifecycle Management program for a jointly developed biologic.

Solution

We evaluated 34 potential indications across respiratory, dermatology, ophthalmology, and other diseases. The project was conducted in stages:

  1. Interviews with key internal stakeholders (across disciplines) to ensure alignment on strategic intent between us and the client; and to rapidly build understanding of known market facts
  2. Desk research, internal data review and interviews, and 40 interviews with KOLs to narrow indications to 14, which were scored by scientific and commercial attractiveness on a proprietary Multi-Variable Analysis (MVA) engine
  3. Use of the MVA engine to identify 4 lead indications jointly with the client, then conducted another 8 KOL interviews, along with 13 payer interviews in the US, UK, France, and Germany to provide a comprehensive view and a path to market for each opportunity

Outcome

  • An agreed upon view on leading potential opportunities, including potential market entry and lifecycle targets.
  • Disease assessments on all 34 indications.
  • A dynamic tool for assessing and visualizing opportunities as market factors change.